Budget impact of lasmiditan for the acute treatment of migraine in the United States

BACKGROUND: Three novel acute treatments for migraine—lasmiditan, ubrogepant, and rimegepant—were approved by the FDA in 2019 and 2020 for adults with migraine with and without aura. American Headache Society guidance recommends that these novel acute treatments be considered for patients who are co...

Descripción completa

Detalles Bibliográficos
Autores principales: Milev, Sandra, Pohl, Gerhardt, Sun, Ariel, Mason, Oksana, Njuguna, Nancy, Loo, Li Shen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391167/
https://www.ncbi.nlm.nih.gov/pubmed/34818093
http://dx.doi.org/10.18553/jmcp.2021.27.12.1714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391167/
https://www.ncbi.nlm.nih.gov/pubmed/34818093
http://dx.doi.org/10.18553/jmcp.2021.27.12.1714

Ejemplares similares